logo

LFMD

LifeMD·NASDAQ
--
--(--)
--
--(--)
7.92 / 10
Outperform

LifeMD's fundamental evaluation is adequate (7.9/10). Key strengths include positive Cash-MV (-0.0673, Quartile 1) and Revenue-MV (0.1747, Quartile 2) differences, along with high year-over-year growth in basic and diluted earnings per share (60.87%). However, concerns remain over Net income-Revenue (-0.1668, Quartile 1) and Net cash flow from operating activities per share (-36.89%), which lag. Total profit growth (74.04%) is a bright spot. Historically, these factors translate to mixed one-month returns and confidence levels, justifying an 'Outperform' stance but with caveats.

Fundamental(7.92)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value0.17
Score3/3
Weight32.75%
1M Return9.68%
Net cash flow from operating activities per share (YoY growth rate %)
Value-36.89
Score0/3
Weight-5.88%
1M Return-2.70%
Net income-Revenue
Value-0.17
Score0/3
Weight-0.56%
1M Return-0.21%
Basic earnings per share (YoY growth rate %)
Value60.87
Score3/3
Weight14.23%
1M Return4.75%
Total profit (YoY growth rate %)
Value74.04
Score3/3
Weight18.51%
1M Return6.14%
Net cash flow from operating activities (YoY growth rate %)
Value-29.68
Score1/3
Weight1.61%
1M Return0.62%
Diluted earnings per share (YoY growth rate %)
Value60.87
Score3/3
Weight15.38%
1M Return5.10%
Asset-MV
Value-0.50
Score1/3
Weight4.99%
1M Return1.95%
Net profit attributable to parent company shareholders (YoY growth rate %)
Value57.77
Score3/3
Weight12.20%
1M Return4.09%
Cash-MV
Value-0.07
Score2/3
Weight6.77%
1M Return2.59%
Is LFMD undervalued or overvalued?
  • LFMD scores 7.92/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, -2.73% net margin, -13.38 P/E ratio, 44.21 P/B ratio, and 56.90% earnings growth, these metrics solidify its Outperform investment rating.